Replies to post #153621 on Biotech Values

[jq1234]

Not clear that cyclin D1 amplification and/or p16 loss actually add as selection markers on top of ER+/HER2-

Agree. The planned ph3 in 1st line ER+/HER2- starting next year don't use the biomarkers tested in ph2 as patient selection criteria.